GEF-Inhibitors: New small molecules for the treatment of autoimmune and malignant diseases
Scientists at the University of Bonn have identified new small molecules which can be used for the treatment of diseases characterized by alterations of proteins which are affected by Guanine nucleotide Exchange Factors (GEFs). Proteins targeted by GEFs are involved in integrin signalling, vesicle transport, or MAPK-signalling. These processes play an important role in the modulation of the immune response. Therefore, abnormal activation of the target proteins of GEFs can cause autoimmune and tumor diseases in humans.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A cause of immunodeficiency identified
After stroke and heart attack: Every year, between 250,000 and 300,000 people in Germany suffer from a stroke or heart attack. These patients suffer immune disturbances and are very frequently…
Wildfire danger to increase due to climate change
WSL Institute for Snow and Avalanche Research (SLF) researchers expect an elevated wildfire danger in the Alpine Foreland from 2040 onwards due to changing meteorological conditions. The danger currently remains…
Advanced Brain Science Without Coding Expertise
Researchers at Helmholtz Munich and the LMU University Hospital Munich introduce DELiVR, offering a new AI-based approach to the complex task of brain cell mapping. The deep learning tool democratizes…
